Atara Biotherapeutics (ATRA) Revenue (2021 - 2026)
Atara Biotherapeutics (ATRA) posted Revenue of $516000.0 for Q1 2026, down 67.65% on a QoQ basis from $1.6 million in Q4 2025, and down 99.47% year-over-year from $98.1 million in Q1 2025.
Atara Biotherapeutics (ATRA) Revenue (2021 - 2026) Analysis & Trends
Atara Biotherapeutics' Revenue history runs 6 years deep, the most recent figure standing at $516000.0 for Q1 2026.
- Quarterly Revenue fell 99.47% year-over-year to $516000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.1 million (down 88.41% YoY) and the FY2025 annual result came in at $120.8 million, down 6.33% from the prior year.
- Revenue was $516000.0 for Q1 2026 at Atara Biotherapeutics, down from $1.6 million in the prior quarter.
- Across five years, Revenue topped out at $98.1 million in Q1 2025 and bottomed at -$3.0 million in Q4 2023.
- A 5-year average of $19.3 million and a median of $4.0 million in 2022 frame the typical range for Revenue.
- Annual changes were most pronounced in 2023 — Revenue slumped 269.77% — and 2024, when it surged 17363.41%.
- Atara Biotherapeutics' Revenue stood at $1.8 million in 2022, then slumped by 269.77% to -$3.0 million in 2023, then jumped by 1188.14% to $32.8 million in 2024, then sank by 95.13% to $1.6 million in 2025, then tumbled by 67.65% to $516000.0 in 2026.
- Business Quant data shows ATRA's Revenue at $516000.0 in Q1 2026, $1.6 million in Q4 2025, and $3.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,981.90 Bn | 66,981.62 Bn | - | - |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.03 Bn | 467.24 Bn | 1.35 Bn | 1.51 Bn |
| 5 | Vertex Pharmaceuticals | 122.09 Bn | 114.84 Bn | 2.59 Bn | 2.99 Bn |
| 6 | Regeneron Pharmaceuticals | 70.01 Bn | 61.26 Bn | 3.31 Bn | 3.61 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.99 Bn | 50.80 Bn | 1.41 Bn | 1.56 Bn |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 1.17 Bn |
| 10 | Atara Biotherapeutics | 109.83 Mn | 101.47 Mn | 392,000.00 | 516,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 516,000.00 |
| Dec 31, 2025 | 1.60 Mn |
| Sep 30, 2025 | 3.45 Mn |
| Jun 30, 2025 | 17.58 Mn |
| Mar 31, 2025 | 98.15 Mn |
| Dec 31, 2024 | 32.75 Mn |
| Sep 30, 2024 | 40.19 Mn |
| Jun 30, 2024 | 28.64 Mn |
| Mar 31, 2024 | 27.36 Mn |
| Dec 31, 2023 | -3.01 Mn |
| Sep 30, 2023 | 2.02 Mn |
| Jun 30, 2023 | 164,000.00 |
| Mar 31, 2023 | 884,000.00 |
| Dec 31, 2022 | 1.77 Mn |
| Sep 30, 2022 | 4.46 Mn |
| Jun 30, 2022 | 51.58 Mn |
| Dec 31, 2021 | 7.55 Mn |
| Sep 30, 2021 | 5.37 Mn |
| Jun 30, 2021 | 3.87 Mn |
| Mar 31, 2021 | 3.55 Mn |